mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma
| Autor: | Henri Braat, Vilvapathy Narayanan, Maikel P. Peppelenbosch, Wesley K. Utomo, Katharina Biermann, Casper H.J. van Eijck, Marco J. Bruno |
|---|---|
| Přispěvatelé: | Gastroenterology & Hepatology, Pathology, Surgery |
| Jazyk: | angličtina |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty endocrine system diseases Disease Biology Flow cytometry 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Pancreatic cancer Cell Line Tumor medicine Autophagy Humans Molecular Targeted Therapy Rapamycin Endoscopic Ultrasound-Guided Fine Needle Aspiration PI3K/AKT/mTOR pathway 030304 developmental biology Sirolimus 0303 health sciences Antibiotics Antineoplastic medicine.diagnostic_test business.industry TOR Serine-Threonine Kinases medicine.disease Immunohistochemistry Personalized medicine digestive system diseases 3. Good health Pancreatic Neoplasms Oncology 030220 oncology & carcinogenesis Cancer cell Cancer research mTOR Adenocarcinoma business Early phase Carcinoma Pancreatic Ductal Signal Transduction |
| Zdroj: | Cancer Letters, 346(2), 309-317. Elsevier Ireland Ltd |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2014.01.014 |
| Popis: | Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease, unusually resistant against therapy. It is generally felt that stratification of patients for personalized medicine is the way forward. Here, we report that a subpopulation of PDACs shows strong activation of the mTOR signaling cassette. Moreover, we show that inhibition of mTOR in pancreatic cancer cell lines showing high levels of mTOR signaling is associated with cancer cell death. Finally, we show using fine needle biopsies the existence of a subpopulation of PDAC patients with high activation of the mTOR signaling cassette and provide evidence that inhibition of mTOR might be clinically useful for this group. Thus, our results define an unrecognized subpopulation of PDACs, characterized by high activation of mTOR and show that identification of this specific patient group in the early phase of diagnosis is feasible. (C) 2014 The Authors. Published by Elsevier Ireland Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|